Tales from the crypts: Regulatory peptides and cytokines in gastrointestinal homeostasis and disease

Journal of Clinical Investigation

Volumn 117, Issue 1, 2007, Pages 6-12

  Merchant, Juanita L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 2051 Basic Science Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GASTROINTESTINAL HORMONE; REGULATOR PROTEIN;

APPETITE; CRYPT CELL; FOOD INTAKE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRACT FUNCTION; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HUMAN; HUNGER; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INTESTINE INNERVATION; NEUROENDOCRINE SYSTEM; NUTRITION; PRIORITY JOURNAL; REVIEW;

CYTOKINES; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMANS; PEPTIDES;

EID: 33846060229     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30974     Document Type: Review

References (80)

1. Gilbert, S.F. 1994. Developmental biology. Sinauer Associates Inc. Sunderland, Massachusetts, USA. 361-368.
2. Ahlman, H., and Nilsson. 2001. The gut as the largest endocrine organ in the body. Ann. Oncol. 12(Suppl. 2):S63-S68.
3. Kelly, D., and Coutts, A.G. 2000. Early nutrition and the development of immune function in the neonate. Proc. Nutr. Soc. 59:177-185.
4. Goyal, R.K., and Hirano, I. 1996. The enteric nervous system. N. Engl. J. Med. 334:1106-1115.
5. Wilson, K.H. 1999. The gastrointestinal biota. In Textbook of gastroenterology. T. Yamada, D.H. Alpers, L. Laine, C. Owyang, and D. Powell, editors. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA. 624-636.
6. Cecil, J.E., Watt, P., Palmer, C.N., and Hetherington, M. 2006. Energy balance and food intake: the role of PPARgamma gene polymorphisms. Physiol. Behav. 88:227-233.
7. Langin, D. 2006. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol. Res. 53:482-491.
8. Jackson, M.B., and Ahima, R.S. 2006. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin. Sci. (Lond.) 110:143-152.
9. Bluher, M. 2005. Transgenic animal models for the study of adipose tissue biology. Best Pract. Res. Clin. Endocrinol. Metab. 19:605-623.
10. Zhang, Y., et al. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:425-431.
11. Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R., and Burn, P. 1995. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 269:546-549.
12. Kojima, M., et al. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 402:656-660.
13. Kojima, M., and Kangawa, K. 2005. Ghrelin: structure and function. Physiol. Rev. 85:495-522.
14. Wortley, K.E., et al. 2005. Absence of ghrelin protects against early-onset obesity. J. Clin. Invest. 115:3573-3578. doi:10.1172/JCI26003.
15. Wortley, K.E., et al. 2004. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc. Natl. Acad. Sci. U. S. A. 101:8227-8232.
16. Cummings, D.E., et al. 2002. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat. Med. 8:643-644.
17. Cummings, D.E., and Overduin, J. 2007. Gastrointestinal regulation of food intake. J. Clin. Invest. 117:13-23. doi:10.1172/JCI30227.
18. Wong, V.S., and Brubaker, P.L. 2006. From cradle to grave: pancreatic beta-cell mass and glucagon-like peptide-1. Minerva Endocrinol. 31:107-124.
19. Heit, J.J., et al. 2006. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 443:345-349.
20. Shapiro, A.M., et al. 2006. International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 355:1318-1330.
21. Drucker, D.J. 2007. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 117:24-32. doi:10.1172/JCI30076.
22. Rendell, M.S., and Jovanovic, L. 2006. Targeting postprandial hyperglycemia. Metabolism. 55:1263-1281.
23. Triplitt, C., Wright, A., and Chiquette, E. 2006. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy. 26:360-374.
24. Gallwitz, B. 2005. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat. Endocrinol. 4:361-370.
25. Kaplan, E.L., et al. 1990. Gastrinomas: a 42-year experience. World J. Surg. 14:365-375; discussion 375-376.
26. Schonhoff, S.E., Giel-Moloney, M., and Leiter, A.B. 2004. Neurogenin 3-expressing progenitor cells in the gastrointestinal tract differentiate into both endocrine and non-endocrine cell types. Dev. Biol. 270:443-454.
27. Lee, C.S., Perreault, N., Brestelli, J.E., and Kaestner, K.H. 2002. Neurogenin 3 is essential for the proper specification of gastric enteroendocrine cells and the maintenance of gastric epithelial cell identity. Genes Dev. 16:1488-1497.
28. Larsson, L.I., Madsen, O.D., Serup, P., Jonsson, J., and Edlund, H. 1996. Pancreatic-duodenal homeobox 1: role in gastric endocrine patterning. Mech. Dev. 60:175-184.
29. Nomura, S., et al. 2005. Evidence for repatterning of the gastric fundic epithelium associated with Ménétrier's disease and TGFalpha overexpression. Gastroenterology. 128:1292-1305.
30. Huang, H.P., et al. 2000. Regulation of the pancreatic islet-specific gene BETA2 (neuroD) by neurogenin 3. Mol. Cell. Biol. 20:3292-3307.
31. Habener, J.F., Kemp, D.M., and Thomas, M.K. 2005. Minireview: transcriptional regulation in pancreatic development. Endocrinology. 146:1025-1034.
32. Wang, J., et al. 2006. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N. Engl. J. Med. 355:270-280.
33. Talley, N.J. 2006. Irritable bowel syndrome. Intern. Med. J. 36:724-728.
34. Mayer, E.A., Naliboff, B., Lee, O., Munakata, J., and Chang, L. 1999. Review article: gender-related differences in functional gastrointestinal disorders. Aliment. Pharmacol. Ther. 13(Suppl. 2):65-69.
35. Stermer, E., Lubezky, A., Potasman, I., Paster, E., and Lavy, A. 2006. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin. Infect. Dis. 43:898-901.
36. Halvorson, H.A., Schlett, C.D., and Riddle, M.S. 2006. Postinfectious irritable bowel syndrome: a meta-analysis. Am. J. Gastroenterol. 101:1894-1899; quiz 1942.
37. Collins, S.M. 2005. Dysregulation of peripheral cytokine production in irritable bowel syndrome. Am. J. Gastroenterol. 100:2517-2518.
38. Riordan, S.M., and Kim, R. 2006. Bacterial over-growth as a cause of irritable bowel syndrome. Curr. Opin. Gastroenterol. 22:669-673.
39. Dinan, T.G., et al. 2006. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 130:304-311.
40. Bhatia, V., and Tandon, R.K. 2005. Stress and the gastrointestinal tract. J. Gastroenterol. Hepatol. 20:332-339.
41. Andresen, V., and Camilleri, M. 2006. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs. 66:1073-1088.
42. Taché, Y., and Bonaz, B. 2007. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J. Clin. Invest. 117:33-40. doi:10.1172/JCI30085.
43. Lee, S.K., and Green, P.H. 2006. Celiac sprue (the great modern-day imposter). Curr. Opin. Rheumatol. 18:101-107.
44. Lewis, N.R., and Scott, B.B. 2006. Systematic review: the use of serology to exclude or diagnose coeliac disease (a comparison of the endomysial and tissue transglutaminase antibody tests). Aliment. Pharmacol. Ther. 24:47-54.
45. Fasano, A., et al. 2003. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch. Intern. Med. 163:286-292.
46. Kagnoff, M.F. 2007. Celiac disease: pathogenesis of a model immunogenetic disease. J. Clin. Invest. 117:41-49. doi:10.1172/JCI30253.
47. See, J., and Murray, J.A. 2006. Gluten-free diet: the medical and nutrition management of celiac disease. Nutr. Clin. Pract. 21:1-15.
48. Brousse, N., and Meijer, J.W. 2005. Malignant complications of coeliac disease. Best Pract. Res. Clin. Gastroenterol. 19:401-412.
49. Kisseleva, T., and Brenner, D.A. 2006. Hepatic stellate cells and the reversal of fibrosis. J. Gastroenterol. Hepatol. 21(Suppl. 3):S84-S87.
50. Friedman, S.L. 2006. Transcriptional regulation of stellate cell activation. J. Gastroenterol. Hepatol. 21(Suppl. 3):S79-S83.
51. Omary, M.B., Lugea, A., Lowe, A.W., and Pandol, S.J. 2007. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J. Clin. Invest. 117:50-59. doi:10.1172/JCI30082.
52. Demetris, A.J., Lunz III, J.G., Specht, S., and Nozaki, I. 2006. Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease. World J. Gastroenterol. 12:3512-3522.
53. Giannelli, G., Quaranta, V., and Antonaci, S. 2003. Tissue remodelling in liver diseases. Histol. Histopathol. 18:1267-1274.
54. Dalgleish, A.G., and O'Byrne, K. 2006. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat. Res. 130:1-38.
55. Direkze, N.C., and Alison, M.R. 2007. Bone marrow and tumour stroma: an intimate relationship. Hematol. Oncol. In press.
56. Tan, B.T., Park, C.Y., Ailles, L.E., and Weissman, I.L. 2006. The cancer stem cell hypothesis: a work in progress. Lab. Invest. 86:1203-1207.
57. Tataria, M., Perryman, S.V., and Sylvester, K.G. 2006. Stem cells: tissue regeneration and cancer. Semin. Pediatr. Surg. 15:284-292.
58. Russo, F.P., et al. 2006. The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 130:1807-1821.
59. Buchholz, M., et al. 2005. Transcriptome analysis of human hepatic and pancreatic stellate cells: organ-specific variations of a common transcriptional phenotype. J. Mol. Med. 83:795-805.
60. Houghton, J., et al. 2004. Gastric cancer originating from bone marrow-derived cells. Science. 306:1568-1571.
61. Fox, J.G., and Wang, T.C. 2007. Inf lammation, atrophy, and gastric cancer. J. Clin. Invest. 117:60-69. doi:10.1172/JCI30111.
62. Merchant, J.L. 2005. Inflammation, atrophy, gastric cancer: connecting the molecular dots. Gastroenterology. 129:1079-1082.
63. Blaser, M.J., and Parsonnet, J. 1994. Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J. Clin. Invest. 94:4-8.
64. Hsing, A.W., et al. 1993. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer. 71:745-750.
65. Correa, P., Haenszel, W., Cuello, C., Tannenbaum, S., and Archer, M. 1975. A model for gastric cancer epidemiology. Lancet. 2:58-60.
66. El-Zimaity, H.M., Ota, H., Graham, D.Y., Akamatsu, T., and Katsuyama, T. 2002. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer. 94:1428-1436.
67. Cormier, J.N., and Vauthey, J.N. 2000. Biliary tract cancer. Curr. Opin. Gastroenterol. 16:437-443.
68. Prinz, C., Schwendy, S., and Voland, P. 2006. H pylori and gastric cancer: shifting the global burden. World J. Gastroenterol. 12:5458-5464.
69. Itzkowitz, S.H. 2006. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol. Clin. North Am. 35:553-571.
70. MacLennan, G.T., et al. 2006. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J. Urol. 176:1012-1016.
71. Aggarwal, B.B., Shishodia, S., Sandur, S.K., Pandey, M.K., and Sethi, G. 2006. Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72:1605-1621.
72. Sharp, R., et al. 1995. Transforming growth factor a disrupts the normal program of cellular differentiation in the gastric mucosa of transgenic mice. Development. 121:149-161.
73. Hochman, J.A., Witte, D.P., and Cohen, M.B. 1996. Diagnosis of cytomegalovirus infection in pediatric Ménétrier's disease by in situ hybridization. J. Clin. Microbiol. 34:2588-2589.
74. Xiao, S.Y., and Hart, J. 2001. Marked gastric foveolar hyperplasia associated with active cytomegalovirus infection. Am. J. Gastroenterol. 96:223-226.
75. Watanabe, K., Beinborn, M., Nagamatsu, S., Ishida, H., and Takahashi, S. 2005. Ménétrier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity. Scand. J. Gastroenterol. 40:477-481.
76. Madisch, A., et al. 2004. Resolution of gastrointestinal protein loss after Helicobacter pylori eradication in a patient with hypertrophic lymphocytic gastritis. Helicobacter. 9:629-631.
77. Wang, T.C., et al. 2000. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 118:36-47.
78. Burdick, J.S., et al. 2000. Treatment of Ménétrier's disease with a monoclonal antibody against the epidermal growth factor receptor. N. Engl. J. Med. 343:1697-1701.
79. Rosnet, O., and Birnbaum, D. 1993. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit. Rev. Oncog. 4:595-613.
80. Coffey, R.J., Washington, M.K., Corless, C.L., and Heinrich, M.C. 2007. Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J. Clin. Invest. 117:70-80. doi:10.1172/JCI30491.